Supplementation with essential phospholipids lowered liver-fat markers in fatty liver disease.
“HbA1c, a marker of average blood sugar levels over the previous 2–3 months, started at about 5.8% with essential phospholipids and 5.7% with placebo. Over six months, it fell by about 0.25 percentage points with essential phospholipids and rose by about 0.30 percentage points with placebo.”